Trial Profile

An Open Label Phase I PET Imaging Study to Investigate the Bio-distribution and Tumor Uptake of [89Zr]Zr-BI 754111 in Patients With Advanced Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma Treated With BI 754111 in Combination With BI 754091

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 19 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ezabenlimab (Primary) ; Miptenalimab (Primary)
Indications Head and neck cancer; Non-small cell lung cancer; Squamous cell cancer
Focus Pharmacokinetics
Sponsors Boehringer Ingelheim

30 Mar 2024 Results assessing safety, maximum tolerated dose (MTD), pharmacokinetics and antitumour activity of ezabenlimab in Study 1381.1 (NCT02952248), Study 1381.4 (NCT03433898) and Study 1381.3 (NCT03780725) published in the Cancer Immunology Immunotherapy.
13 Sep 2021 Status changed from completed to discontinued.
17 Dec 2020 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com